Sacituzumab govitecan is an ADC that recognizes trophoblast cell-surface antigen 2 (Trop-2)—a cell-surface glycoprotein highly expressed in aggressive bladder cancers. The gene discussed is TACSTD2; the disease is urinary bladder cancer.